Rare variants of melanoma

Understanding the names of rare forms

“Rare” does not identify a single biological behaviour. Some names describe cells under the microscope, while others describe the site or setting in which melanoma occurs. These categories are not always mutually exclusive: a melanoma can have several features at once.

This distinction prevents a word in a pathology report from being treated as an automatic prediction of prognosis. A complete diagnosis, site of origin, invasion and disease extent remain essential. Variants documented in few cases have a more limited evidence base than better-studied forms.

Variants defined by microscopic appearance

Nevoid melanoma can resemble a benign mole, including within tissue. Small cell melanoma describes a morphology that can overlap with the nevoid pattern. These names do not automatically mean that a tumour arose from a pre-existing mole.

Signet ring cell melanoma and rhabdoid melanoma are named after cellular appearances. Myxoid melanoma has a distinctive extracellular matrix. Osteogenic melanoma may produce osteoid or show osteocartilaginous differentiation. These are pathology topics, not forms that can be reliably identified by looking at the skin.

Origin, site and age at onset

Melanoma arising in a blue nevus concerns association with a particular melanocytic lesion; the common blue nevus is benign and transformation is rare. Congenital or infantile melanoma concerns age at presentation and includes different situations requiring specialist paediatric assessment.

Primary mucosal melanoma is grouped here because it is rare, but is defined mainly by its site. It is also linked from special types of melanoma alongside the eye and nervous system pathways. Each page links back to its index and to relevant further reading without requiring a return to the home page.

From pathology report to clinical decision

Histological examination and immunohistochemistry help distinguish these variants from other tumours. Difficult cases may benefit from slide review at an expert centre or molecular investigations. A positive or negative marker, separated from the other findings, cannot establish diagnosis and treatment.

Care is selected according to site, stage, surgical options and biological features, considering the available evidence. Rarity alone does not prove that treatment is ineffective or justify generalising from one case. Bring the complete report to the consultation and ask which findings are established and which remain uncertain.

Sources and update

Editorial revision: 17 October 2026. This information does not replace medical assessment. For very rare variants, some evidence comes from small series or case reports.